Study Seeks Young Children With Autism, PDD
The University of Arizona psychiatry department is seeking volunteers to participate in a medication study on children with autism or Pervasive Developmental Disorders.
Dr. Jaswinder Ghuman and her research team are conducting a study to evaluate the effects of medicine, methylphenidate, to treat problems with hyperactivity, impulsiveness and distractibility in 3-6 year old children with autism or Pervasive Developmental Disorders (PDD).
Boys and girls ages 3-6 years of age who have been diagnosed or suspected to have autism/PDD or have problems with social interaction and development are eligible. Also eligible are children who have problems with hyperactivity, impulsiveness and distractibility for at least 6 months and are currently attending an early intervention program, a behavior program, preschool or school.
Parents or caretakers of participants will be given information to help in understanding hyperactivity, impulsiveness and distractibility problems in children with autism and PDD and help other individuals or families living with children with autism and PDD.
The medication treatment, methylphenidate, targets symptoms in children of hyperactivity, constant fidgeting, squirming, always “on the go”, not waiting their turn, interrupting, impulsivity, and easily distracted.
Services to children participating in the study are free along with the medication. A child psychiatrist and other members of the research team will evaluate the child with parent and teacher input to determine if your child has autism/PDD and problems with hyperactivity, impulsiveness and distractibility. Doctors will make an evaluation to see if a child needs medication. A physician will monitor the medication using information from teachers and weekly visits with patient, parent.